INTRODUCTION {#s1}
============

Intracranial aneurysm (IA) is characterized by pathological dilatation intracranial artery as a pouch. Till now, IA rupture has been one of the most serious neurological diseases \[[@R1]\]. Early diagnosis of IA and prevention of rupture and bleeding are of important clinical significance. At present, diagnosis, prognosis, and evaluation of IA mainly depend on imaging, hemodynamics, and biological model construction \[[@R2]\]. Molecular biology studies have attracted more attention currently. The clinical manifestation of IA is abnormal dilatation of intracranial arteries, and thinning and weakening of the arterial wall by constantly impacting the vessel wall, thereby increasing the risk of aneurysm rupture \[[@R3]\]. IA occurs 2%-5% of the world population; and approximately 0.7%-1.9% of IA patients have ruptured, which cause life-threatening subarachnoid hemorrhage (SAH) \[[@R4]\]. IA is one of the most devastating neurological diseases due to its high mortality and poor prognosis. It is characterized by spontaneous intracerebral hemorrhage, cerebral vasospasm, and oculomotor nerve palsy \[[@R5]\]. Unfortunately, IA in most patients is asymptomatic until the tumor ruptures and pain appears and leads to subarachnoid hemorrhage \[[@R6]\]. Although surgery has improved, the prognosis of SAH hasn't ameliorated in the past few decades, and the mortality rate is up to 40%, about half of the survivors are insufficiency \[[@R7], [@R8]\]. Hemodynamic disturbances, genetic abnormalities, infection, aging, and congenital factors are the common risk factors of the occurrence and progression of IA \[[@R9]\]. However, the pathogenesis of aneurysms remains unknown. In this context, it is urgent to identify biomolecules associated with the diagnosis and prognosis of IA.

Circular RNAs (circRNAs) are endogenous RNA with stable structure and highly tissue specific expression \[[@R10]\]. circRNAs are common in mammalian cells and regulate gene expression at the transcriptional or post transcriptional levels by interacting with microRNA or other molecules \[[@R11], [@R12]\]. circRNAs are different from linear RNAs because of remarkable non-standard splicing characteristics and no characteristic of free 3 'or' 5 'ends \[[@R13]\]. Recently, researchers have found that circRNAs are involved in the development of many diseases, such as atherosclerosis and nervous system diseases \[[@R14]\]. Present studies have shown that circRNAs have many functions, such as miRNA sponges, gene regulation, and close relation with cell function and diseases.

circRNAs end to end without free ends and can tolerate nuclease RNase R. Their structures are more stable than miRNA \[[@R15]\]. circRNAs widely spread in the blood, which makes them become potential noninvasive candidate biomarker resources \[[@R16]\]. However, little is known about their associations with cancers. In this study, we focused on a circRNA, hsa_circ_0021001 that locates at chr11:6499967-6501693 in circBase with its associated-gene symbol as ARFIP2 because hsa_circ_0021001 has been predicted to be associated with IA in circ2Traits (ID: hsa_circ_0021001 in database circ2Traits) 22. We first validated the expression of hsa_circ_0021001 in IA patients. Then we explored the role of hsa_circ_0021001 in the diagnosis and prognosis of IA. Our findings suggested that hsa_circ_0021001 may serve as a potential novel biomarker for IA.

RESULTS {#s2}
=======

Detection of hsa_circ_0021001 in IA patients {#s2_1}
--------------------------------------------

Sanger sequencing confirmed the presence of hsa_circ_0021001 back-splicing site, demonstrating that hsa_circ_0021001 exists in a ring structure in nature (Figure [1](#F1){ref-type="fig"}).

![Identification of hsa_circ_0021001 in IA patients\
**(A)** hsa_circ_0021001 is produced at the ARFIP2 gene locus containing exon 2-5; **(B)** Sanger sequencing of hsa_circ_0021001 showed the back-splice junction.](oncotarget-08-107125-g001){#F1}

Down-expression of hsa_circ_0021001 in IA patients {#s2_2}
--------------------------------------------------

In order to determine the difference in hsa_circ_0021001 expression between IA patients and healthy controls, total RNA of peripheral blood was isolated from 223 IA patients and 131 normal controls and analyzed by qRT-PCR. The expression of hsa_circ_0021001 in both groups was detected by qRT-PCR. Our results showed that hsa_circ_0021001 expression in IA patients was significantly lower than that in healthy controls (n = 131; P = 0.0014) (Figure [2A](#F2){ref-type="fig"}). The AUC of hsa_circ_0021001ROC was 0.87 (95% confidence interval (CI): 0.784-0.963). The specificity was 0.92 and sensitivity was 0.81, with diagnostic threshold of 20.74 (Figure [2B](#F2){ref-type="fig"}).

![Hsa_circ_0021001 expression level in IA development\
**(A)** hsa_circ_0021001 expression in the experimental and control groups; **(B)** ROC curve for detection of the diagnostic efficiency of hsa_circ_0021001 in IA with an AUC of 0.87, a sensitivity of 0.81 and a specificity of 0.92. ROC curve: Receiver Operating Characteristic curve; AUC: area under the ROC curve.](oncotarget-08-107125-g002){#F2}

The potential diagnostic value of hsa_circ_0021001 for IA {#s2_3}
---------------------------------------------------------

The results showed that the expression of hsa_circ_0021001 was significantly decreased in blood samples of IA, so we analyzed the relationship between hsa_circ_0021001 expression and the clinicopathological features of IA. As shown in Table [1](#T1){ref-type="table"}, hsa_circ_0021001 expression was not significantly associated with age, gender, size of aneurysm, hypertension history, smoking, alcohol consumption, coronary heart disease, blood glucose, and aneurysm location (P\>0.05). But, hsa_circ_0021001 expression was significantly associated with aneurysm rupture, Hunt Hess levels, and timing of surgery (P\< 0.05).

###### Association between hsa_circ_0021001 expression and clinicopathologic characteristics of intracranial aneurysm

  Clinicopathologic parameter         Case number (n)   High hsa_circ_0021001 expression \[n(%)\]   Low hsa_circ_0021001 expression \[n(%)\]   χ2      P
  ----------------------------------- ----------------- ------------------------------------------- ------------------------------------------ ------- ---------
  Age (year)                                                                                                                                           
   ≥55                                89                21 (23.6%)                                  68 (76.4%)                                 2.624   0.103
   \<55                               134               18 (13.4%)                                  116 (86.6%)                                        
  Gender                                                                                                                                               
   Male                               144               29 (20.1%)                                  115 (79.9%)                                0.285   0.712
   Female                             79                9 (11.4%)                                   70 (88.6%)                                         
  Aneurysm size (mm)                                                                                                                                   
   ≥10                                80                10 (12.5%)                                  70 (87.5%)                                 0.370   0.617
   \<10                               143               27 (18.9%)                                  116 (81.1%)                                        
  History of hypertension                                                                                                                              
   Yes                                97                22 (22.7%)                                  75 (77.3%)                                 2.758   0.226
   No                                 126               17 (13.5%)                                  109 (86.5%)                                        
  History of smoking and drinking                                                                                                              1.261   0.307
   Yes                                113               16 (14.2%)                                  97 (85.8%)                                         
   No                                 110               23 (20.9%)                                  87 (79.1%)                                         
  History of coronary heart disease                                                                                                            0.154   0.672
   Yes                                71                12 (16.9%)                                  59 (83.1%)                                         
   No                                 152               27 (17.8%)                                  125 (82.2%)                                        
  Blood glucose (mmol/L)                                                                                                                       0.283   0.545
   \>5                                80                13 (16.3%)                                  67 (83.7%)                                         
   \<5                                143               27 (18.9%)                                  116 (81.1%)                                        
  Aneurysm location                                                                                                                            1.482   0.324
   Anterior circulation aneurysm      196               31 (15.8%)                                  165 (84.2%)                                        
   Posterior circulation aneurysm     27                5 (25.0%)                                   15 (75.0%)                                         
  Rupture                                                                                                                                      9.018   0.002
   Ruptured                           162               19 (11.7%)                                  143 (88.3%)                                        
   Unruptured                         61                19 (31.1%)                                  42 (68.9%)                                         
  Hunt-Hess grading                                                                                                                            21.03   \<0.001
   Level I ∼ III                      146               11 (7.5%)                                   135 (92.5%)                                        
   Level IV ∼ V                       77                26 (33.8%)                                  51 (66.2%)                                         
  Surgical timing                                                                                                                              13.16   0.005
   Early-phase surgery                110               13 (11.8%)                                  97 (88.2%)                                         
   Middle-phase surgery               68                7 (10.3%)                                   61 (89.7%)                                         
   Late-phase surgery                 45                13 (28.9%)                                  32 (71.1%)                                         

Relationship between hsa_circ_0021001 and GOS in IA patients {#s2_4}
------------------------------------------------------------

According to our data, GOS was not significantly correlated with age, gender, tumor size, coronary heart disease, smoking, alcohol consumption, blood glucose and timing of surgery (P\>0.05); while GOS was significantly associated with hypertension history, aneurysm location, rupture, Hunt Hess levels (P\<0.05) (Table [2](#T2){ref-type="table"}).

###### Associations of GOS with hsa_circ_0021001 expression and clinicopathologic features of IA

  Prognostic factors                  n     Good prognosis \[n(%)\]   Poor prognosis \[n(%)\]   χ2       P
  ----------------------------------- ----- ------------------------- ------------------------- -------- ---------
  Age (year)                                                                                    0.681    0.513
   ≥55                                89    73 (82.0%)                16 (18.0%)                         
   \<55                               134   105 (78.4%)               29 (21.6%)                         
  Gender                                                                                        3.115    0.231
   Male                               144   111 (77.1%)               33 (22.9%)                         
   Female                             79    69 (87.3%)                10 (12.7%)                         
  Aneurysm size (mm)                                                                            0.782    0.503
   ≥10                                80    67 (83.7%)                13 (16.3%)                         
   \<10                               143   113 (79.0%)               30 (21.0%)                         
  History of hypertension                                                                       12.304   0.002
   Yes                                97    90 (92.8%)                7 (7.2%)                           
   No                                 126   90 (71.4%)                36 (28.6%)                         
  History of smoking and drinking                                                               5.381    0.072
   Yes                                113   98 (86.7%)                15 (13.3%)                         
   No                                 110   83 (75.5%)                27 (24.5%)                         
  History of coronary heart disease                                                             0.683    0.504
   Yes                                71    58 (81.7%)                13 (18.3%)                         
   No                                 152   125 (82.2%)               27 (17.8%)                         
  Blood glucose (mmol/L)                                                                        3.320    0.265
   \>5                                80    59 (73.8%)                21 (26.2%)                         
   \<5                                143   113 (79.0%)               30 (21.0%)                         
  Aneurysm location                                                                             14.644   \<0.001
   Anterior circulation aneurysm      196   173 (88.3%)               23 (11.7%)                         
   Posterior circulation aneurysm     27    13 (48.1%)                14 (51.9%)                         
  Rupture                                                                                       15.87    \<0.001
   Ruptured                           162   138 (85.2%)               24 (14.8%)                         
   Unruptured                         61    32 (52.5%)                29 (47.5%)                         
  Hunt-Hess grading                                                                             11.06    0.003
   Level I ∼ III                      146   127 (87.0%)               19 (13.0%)                         
   Level IV ∼ V                       77    53 (68.8%)                24 (31.2%)                         
  Surgical timing                                                                               0.404    0.970
   Early-phase surgery                110   89 (80.9%)                21 (19.1%)                         
   Middle-phase surgery               68    56 (82.4%)                12 (17.6%)                         
   Late-phase surgery                 45    37 (82.2%)                8 (17.8%)                          
  hsa_circ_0021001                                                                              6.866    0.007
   High expression                    39    26 (66.7%)                13 (33.3%)                         
   Low expression                     184   157 (85.3%)               27 (14.7%)                         

GOS, Glasgow Prognosis Score; IA, intracranial aneurysm.

Results of follow up and risk factors {#s2_5}
-------------------------------------

As shown by the survival curve, 8 cases were lost follow-up during the five years. DFS and OS were significantly longer in IA patients with higher expression of hsa_circ_0021001 than those with low expression (DFS: 33.1 vs 26.9, P = 0.013; OS: 32.2 vs 25.1, P = 0.005) (Figure [3](#F3){ref-type="fig"}). The Cox regression model showed that hsa_circ_0021001 expression, aneurysm location, rupture, and Hunt-Hess levels were the prognostic risk factors for IA (Table [3](#T3){ref-type="table"}).

![Kaplan-Meier analysis of survival rate of IA patients according to the expression status of hsa_circ_0021001\
**(A)** association between hsa_circ_0021001 expression and DFS, P\<0.05 in the Log-rank test; **(B)** Association between hsa_circ_0021001 expression and OS, P\<0.05 in the Log-rank test. DFS: disease-free survival; OS: overall survival.](oncotarget-08-107125-g003){#F3}

###### Risk factors to IA prognosis by multivariate Cox proportional hazards regression analysis

                                B       SE      Wald     df   Sig.      Exp (B)   95.0% CI for Exp (B)   
  ----------------------------- ------- ------- -------- ---- --------- --------- ---------------------- --------
  Hsa_circ_0021001 expression   2.307   1.036   4.586    1    0.03      9.371     1.147                  67.051
  Hypertension                  0.335   0.286   0.642    1    0.503     1.365     0.692                  2.33
  Aneurysm location             1.306   0.304   15.334   1    \<0.001   3.810     1.774                  7.024
  Rupture                       1.892   0.815   8.067    1    0.007     7.226     1.641                  28.631
  Hunt-Hess grading             1.130   0.310   11.283   1    \<0.001   2.714     1.503                  5.408

IA, intracranial aneurysm; B, regression coefficient; SE, standard error of regression coefficient; Wald, test statistics; df, degree of freedom. Sig., significance; Exp (B). index of the regression coefficients; CI, confidence interval.

DISCUSSIONS {#s3}
===========

Our results showed that hsa_circ_0021001 expression was significantly lower in IA patients than that in healthy controls. The expression of hsa_circ_0021001 was significantly associated with aneurysm rupture, Hunt Hess levels, and timing of surgery (P\<0.05). Moreover, we found that IA patients with high expression of hsa_circ_0021001 had longer DFS and OS than patients with low hsa_circ_0021001 expression. Our results further suggested that downregulation of hsa_circ_0021001 was associated with shorter survival of IA patients. ROC analysis proved that hsa_circ_0021001 can be used as a biomarker for IA with high accuracy, sensitivity, and specificity.

Circular RNAs were found to act as competitive endogenous RNAs binding proteins (protein sponges) \[[@R17], [@R18]\]. circRNAs regulate gene expression by a variety of mechanisms: some circRNAs can act as microRNA (miRNA) sponges, playing a competitive role in binding miRNA by post transcriptional regulation \[[@R19]\]; some circRNAs can also modulate transcription by interacting with nuclear small RNA (snRNA) or RNA polymerase II \[[@R20]\]; some circRNAs can modulate RNA splicing by binding to transcription factors \[[@R21]\]. circRNAs play an important role in various diseases, such as cancer, atherosclerosis, arthritis, pulmonary fibrosis, myotonic dystrophy, and Alzheimer's disease \[[@R22]--[@R24]\]. For example, hsa_circ_002059 can be used as a new biomarker for gastric cancer \[[@R25]\]. circRNAs are used as clinical diagnosis tools for esophageal carcinoma \[[@R26]\]. Hsa_circ_0005075 can be a potential biomarker for hepatocellular carcinoma \[[@R27]\]. In this study, we focused on hsa_circ_0021001 and found its potential RNA binding protein (RBP) binding site (starBase, V2.0). These results indicated that hsa_circ_0021001 participates in and promotes the development of IA as protein sponge or transcription regulator. Two circRNAs have been proved to be miRNA sponges in mammals \[[@R25], [@R28]\]. A specific circRNA (cirs-7, also known as CDR1as), has more than 70 binding sites of miR-7. circRNA has been reported to impair miR-7 regulation *in vivo*. The second circRNA is a testis specific transcript which can determine the expression of male determining gene SRY. It contains 16 binding sites of miR-138. Many miRNA binding sites on circRNAs are predicted to have function. These results imply that hsa_circ_0021001 may play an important role in tumorigenesis and metastasis of IA by interaction with miRNA.

In conclusion, we first identified a significant decrease in the expression of hsa_circ_0021001 in IA patients, which may serve as a potential novel biomarker for IA. Moreover, our findings suggest that hsa_circ_0021001 may be involved in the genesis and metastasis of IA.

MATERIALS AND METHODS {#s4}
=====================

Study population {#s4_1}
----------------

A cohort of 223 cases of IA patients who were admitted in the department of neurosurgery in the First People's Hospital of Wenling from January 2009 to July 2012 were collected as the experimental group, and 131 healthy volunteers over the same period served as the control group. After admission, all patients underwent computed tomography (CT) examinations and diagnosed by three-dimensional computed tomography angiography (3D.CTA) or digital subtraction angiography (DSA) before surgery. Exclusion criteria: patients suffering from other serious cardiovascular or cerebrovascular diseases; patients with other serious organs diseases; patients with incomplete clinical data. 223 cases of IA patients included 141 males and 82 females. The age range was 20-77 years, and the average age was 52 years. The imaging data of IA patients in this study showed that the diameter of the aneurysm \<5 mm in 38 cases, between 5 mm-10 mm in124 cases, more than 10 mm in 61 cases, anterior circulation aneurysms in 204 cases, posterior circulation aneurysms in 19 cases; ruptured aneurysm in 130 cases, unruptured aneurysm in 80 cases. There was no significant difference in age, gender, blood pressure, blood sugar, blood lipid, and smoking between the experimental group and the control group (Table [1](#T1){ref-type="table"}). Blood pressure examination included hypertension history, treatment, systolic and diastolic pressure, mean pressure at admission. Blood sugar examination included diabetes history, blood sugar abnormality history, treatment, and fasting blood sugar at admission. Blood lipids examination included hyperlipidemia history, treatment, triglycerid, cholesterol, high-density lipoprotein, and low-density lipoprotein at admission. Smoking history included a calculation of the average annual smoking amount based on smoking years and the number of smoked cigarettes per day. All participants signed written informed consent.

Blood sample collection {#s4_2}
-----------------------

Blood samples were collected at fasting in the early morning by a vacuum collecting vessel, then stored at 4°C. They were processed in 6 h. Samples were centrifuged at 1600 g/min, 12 min, and then blood cell components were removed. The upper plasma/serum were transferred into a new sterile RNase-free centrifuge tube, centrifuged at 14000 g/min, 16 min. Large granular material such as cell debris was removed, and the upper plasma/serum was transferred into a new 1.5 ml RNase-free centrifuge tube and stored immediately at -80°C.

Total RNA extraction {#s4_3}
--------------------

RNA was extracted from the whole blood plasma according to the manufacture's instruction (QIAGEN, Valencia, CA, USA). Then the optical density (OD) 260/280 was determined by ultraviolet spectrophotometry. After calculating the concentration, RNA was frozen in -80°C refrigerator.

Detection of hsa_circ_0021001 expression by real-time quantitative PCR {#s4_4}
----------------------------------------------------------------------

qRT-PCR experiment was performed using GoTaq qPCR Master Mix kit and Mx3005P real-time PCR operating system. According to the procedures of the kit, 25 μL reaction systems consisted of 5 μL cDNA products, 5.5 μL DEPC water, 1 μL upstream primers, 1 μL downstream primers, and 12.5 μL qPCR mixtures. Hsa_circ_0021001 primers and GAPDH primers were synthesized by Shanghai Sangon biotechnology Inc. The primer sequences of hsa_circ_0021001 were as follows: 5′-GAAACTCGAGCCGCGCTGCGATATGTG-3′ (upstream); 5′-CACAGCCAGCAAAGTTACTCGCTTTAAA-3′ (downstream). GAPDH was used as an internal standard. The primer sequences of GAPDH were as follows: 5′-CCCGATAACACAAGTGCAGC-3′ (upstream); 5′-CCCGATAACACAAGTGCAGC -3′ (downstream). The relative expression of hsa_circ_0021001 was calculated using 2^−ΔΔCt^. All data were expressed as mean ± SD of three independent experiments. The experiments were performed by blind method.

Sanger sequencing {#s4_5}
-----------------

The target fragment was inserted into a T vector and the length was determined by Sanger. The following primers were designed by Shanghai Sangon biotechnology Inc to test the back-splicing site of hsa_circ_0021001: 5′- CAATGCTGAAAACTGCTGAGAGAAG-3′ (upstream); 5′-CCTGCATTCTCTTTTCTGTTGTATCTTTAA-3′ (downstream).

Prognosis and follow-up {#s4_6}
-----------------------

The follow-up was conducted by telephone and clinical for 3 years. The prognosis after surgery was determined by Glasgow prognostic score (GOS). The follow-up was from the hospital discharge time after the patient was treated to January 2015. For survival patients at the end of the follow-up visit, the follow-up data were the last contact state. For patients lost follow-up, the follow-up data were the last census state. The survival time was expressed by survival months. Overall survival (OS) was the duration from aneurysm neck clipping to the death of the patient, and the disease-free survival (DFS) was the period at which the operation started without recurrence or death due to IA.

Statistical analysis {#s4_7}
--------------------

All data were analyzed by R software (V, 2.15.0, [Http://www.r-project.org/](http://www.r-project.org/)). The difference in hsa_circ_0021001 expression between IA patients and normal healthy controls were analyzed by paired *t-test*. The relationship between hsa_circ_0021001 and clinicopathological factors was evaluated by one-way ANOVA. ROC curve was drawn to access the diagnosis value. Cutoff value of hsa_circ_0021001 was analyzed by SigmaPlot 12.3. The survival curve was drawn by Kaplan--Meier method and analyzed by Long-rank test. Multivariate Cox proportional hazards regression analysis was used to analyze the prognosis. P\<0.05 was considered statistically significant. The experiment repeatability was determined by Pearson correlation test.
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